Press release
Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the appointment of Dr. An van Es-Johansson, M.D.
About this update from Savara, Inc.
[{"type":"text","content":" AUSTIN, Texas--(BUSINESS WIRE)--\nSavara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the appointment of Dr. An van Es-Johansson, M.D. to its Board of Directors, effective immediately. Dr. van Es-Johansson has extensive experience in the development of FDA- and EMA-approved orphan products and has held global leadership roles across multiple disciplines of the life sciences industry, including clinical development, regulatory, and medical affairs.\n\n\nDr. van Es-Johansson, an expert in orphan drug development, is currently the Chief Medical Officer for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer’s disease, where she is responsible for regulatory, clinical development, clinical operations, and pharmacovigilance. For more than a decade prior to that, Dr. van Es-Johansson was at Sobi, an international rare disease company headquartered in Stockholm, Sweden. During her tenure at Sobi, she held a range of executive roles of increasing responsibility. Dr. van Es-Johansson has leadership experience within large pharmaceutical and smaller biotechnology companies, including Roche, Eli Lilly, Active Biotech, and BioStratum.\n\n\n“I am pleased to be joining a team so passionate about improving the lives of patients with a rare lung disease,” said Dr. van Es-Johansson. “I am excited to be working with the board of directors and executive team as they navigate the regulatory pathway for the Molgradex aPAP program. Through this opportunity, I look forward to sharing my insights and experience in bringing orphan drugs to market for patients as well as contributing to the future success of the company.”\n\n\n“Dr. van Es-Johansson brings deep expertise in orphan drug development and we are fortunate to have her join Savara’s Board of Directors,” said Rob Neville, Chief Executive Officer, Savara. “We believe her global regulatory experience, and extensive knowledge of the drug development process that spans clinical operations through to commercialization, will be a true asset to our company and the patients we serve. Her appointment will also help ensure that our Board continues to benefit from a breadth of diverse perspectives, experience, and knowledge.”\n\n\nDr. van Es-Johansson received a M.D. from Erasmus University, Rotterdam, The Netherlands.\n\n\nAbout Savara\n\n\nSavara i...